Media Enquiries T: +44 (0)14 2334 0362 E: rosetta.doughty@oraca.net W: <u>www.oraca.net</u> ORACA Ltd Independent Equity Research 17th Willow Street, 3rd floor London, EC2A 4BH



PRESS RELEASE

ORACA Announces Launch of its Life Sciences Sector

Independent equity research house launches coverage of European large cap Pharma, European Biotech and strengthen Nanotech industry expertise through the Life Sciences sector product

London, 18th November 2009: Independent equity research house, ORACA, announced today the launch of its new sector, Life Sciences. The team will cover the Pharma, Biotech and Nanotech industries.

In recent years the Life Sciences sector has grown in almost every developed country in line with demographic changes. Pharmaceutical companies have infused capital to expand geographically and investors are also backing upcoming companies looking to increase their market share internationally.

Christopher Nicholson, Director and Lead Equity Analyst, ORACA said: "With an ever-growing aging population in the developed economies and a globally more informed public, aware of their healthcare options, ORACA recognised it needed to offer its clients truly independent coverage of this major industry."

He continued: "Consumers in the developed and emerging economies are spending ever-more on health and wellness products and services. We see technology providing the push for companies to produce cheaper healthcare offerings, opening up new markets in the developing world and expanding those in North America, Europe and the BRIC countries in particular." -end-

About ORACA: Founded in November 1999, ORACA, first of the independent equity analyst groups in London, has a completely independent ethos. Our brand and service proposition is unbiased, credible and effective. We have a reputation for delivery on time and in budget. ORACA has developed a highly regarded equity research & distribution service. We offer a wide range of capital markets & consultancy products and services. Our collective expertise covers TMT (Telecom/Media/Tech), Extractives (Oil/Gas/Mining), CleanTech (Bio fuels/Solar/Winds), Life Sciences (Pharma/Bio/Nanotech) and Macroeconomics research sectors.